Related Experiment Video

Updated: Dec 30, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.9K

Extracellular Vesicles for Cancer Therapy: Impact of Host Immune Response

Katie E Gilligan1, Róisín M Dwyer1,2

  • 1Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway (NUIG), H91 YR71 Galway, Ireland.

Cells
|January 23, 2020
PubMed

Insights

Extracellular vesicles (EVs) show promise as cancer therapeutics due to their targeting ability and customizable contents. Understanding the immune response to EV administration is crucial for clinical applications.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Extracellular vesicles (EVs) are emerging as promising cancer therapeutics.
  • EVs offer advantages over cell-based carriers, including ease of manipulation and tumor-targeting potential.
  • Standardization of EV nomenclature, isolation, and characterization is ongoing.

Purpose of the Study:

  • To review studies on the immune response to extracellular vesicle (EV) administration in cancer therapy.
  • To highlight the critical importance of understanding immune reactions as EV therapy advances to clinical settings.

Main Methods:

  • Literature review of studies investigating EVs as cancer therapeutics.
  • Focus on studies reporting on the immune response elicited by EV administration.

Main Results:

  • Extracellular vesicles (EVs) are being explored for their therapeutic potential in cancer treatment.
  • Research highlights the ability to modify EV contents for enhanced efficacy and tumor targeting.
  • The immune response to EV administration is a key consideration for clinical translation.

Conclusions:

  • Extracellular vesicles (EVs) represent a viable platform for cancer therapy development.
  • Further research into the immunogenicity of EVs is essential for safe and effective clinical application.
  • The immune response to EVs is a critical factor determining their success as cancer therapeutics.
Keywords:
cancerextracellular vesiclesimmune response

More Related Videos

Characterization of Immune Cell-derived Extracellular Vesicles and Studying Functional Impact on Cell Environment10:09

Characterization of Immune Cell-derived Extracellular Vesicles and Studying Functional Impact on Cell Environment

Published on: June 2, 2020

7.2K
Evaluation of the Storage Stability of Extracellular Vesicles11:31

Evaluation of the Storage Stability of Extracellular Vesicles

Published on: May 22, 2019

14.9K

Related Concept Videos

Overview of Exosomes01:36

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
884
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.5K